Skip to main navigation

Tests
- Diseases areas
  Cancer
  Other
  - Interstitial lung disease
- Products
  Thyroid Cancer
  - Afirma Genomic Sequencing Classifier
  Prostate Cancer
  - Decipher Prostate Genomic Classifier
  Breast Cancer
  - Prosigna Breast Cancer Assay
  Interstitial Lung Disease
  - Envisia Genomic Classifier
  Bladder Cancer
  - Decipher Bladder Genomic Classifier
- Pipeline
- Publications
Partner Services
- Biopharma services
- IVD services
Company
- About us
- Contact
News & Events
- News
  - Press releases
  - In the news
- Events
Careers
- Culture
- Job Openings
Investors

Tests
Cancer

Thyroid cancer

Prostate cancer

Lung cancer

Breast cancer

Bladder cancer

Other

Interstitial lung disease

Portfolio and test expansion
Thyroid Cancer

Afirma Genomic Sequencing Classifier

Prostate Cancer

Decipher Prostate Genomic Classifier

Breast Cancer

Prosigna Breast Cancer Assay

Interstitial Lung Disease

Envisia Genomic Classifier

Bladder Cancer

Decipher Bladder Genomic Classifier

Instructions for use

Quality certificates

Safety data sheet

Enabling global access
Portfolio and test expansion

Enabling global access

MRD technology

Who we are
Partner Services
- Biopharma services
- IVD services
Company
- About us
- Contact
Who we are

Leadership

Corporate recognition

Culture
News & Events
- News
- Events
Press releases

In the news

Who we are
Careers
- Culture
- Job Openings
Investors
SEC filings

Quarterly results

Annual reports

Stock information

Analyst coverage

ESG information
Governance overview

Board of directors

Committee composition

Leadership

ESG information

Annual reports
Investor FAQs

Information request

Email alerts

Annual reports

Press Releases

Items Per Page

Year

Jan 09, 2012

Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis

Read More

Sep 01, 2011

New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results

Read More

Sep 15, 2010

New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples

Read More

Jun 09, 2010

Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product

Read More

Pagination

First page
Previous page
…
Page 50
Page 51
Current page 52

Displaying 511 - 514 of 514

Contact Investor Relations

Please feel free to contact us if you have questions or would like additional investor relations information:

investors@veracyte.com
+1 619.393.1545

Shareholder Tools

menu_book Printed Materials
print Print
share Share

Subscribe to Investor Alerts

Sign up

© 2024 Veracyte, Inc. All rights reserved.

Offices

South San Francisco, CA

6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
Marseille, France

163 Avenue de Luminy
13009 Marseille
FRANCE
San Diego, CA

6925 Lusk Boulevard, Suite 200
San Diego, CA 92121
Austin, TX

12357-A Riata Trace Parkway
Building 5, Suite 100
Austin, TX 78727
Haifa, Israel

Nahum Het 7
3508506 Haifa, Israel
ISRAEL

Helpful links

Privacy Policy
HIPAA Notice of Privacy Practices (PDF)
Terms of Use
Terms of Sale
No Surprise Act
Business ethics and compliance
Accessibility
Cookie Settings

Connect

Contact
LinkedIn
X (Twitter)
YouTube

Facebook
Twitter
LinkedIn